Pharmacogenetics: from bench to byte—an update of guidelines
JJ Swen, M Nijenhuis, A de Boer… - Clinical …, 2011 - Wiley Online Library
Currently, there are very few guidelines linking the results of pharmacogenetic tests to
specific therapeutic recommendations. Therefore, the Royal Dutch Association for the …
specific therapeutic recommendations. Therefore, the Royal Dutch Association for the …
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with
some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes …
some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes …
Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group
PCD Bank, KE Caudle, JJ Swen… - Clinical …, 2018 - Wiley Online Library
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
JJ Swen, CH van der Wouden, LEN Manson… - The Lancet, 2023 - thelancet.com
Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of …
well documented for several single gene–drug combinations. However, the clinical utility of …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …
[HTML][HTML] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants …
Abstract CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of
tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (eg …
tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (eg …
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update
…, J Barbarino, JHM Schellens, JJ Swen… - Clinical …, 2018 - Wiley Online Library
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and …
…, K Sangkuhl, M Whirl‐Carrillo, JJ Swen… - Clinical and …, 2020 - Wiley Online Library
Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
…, RHN van Schaik, RHJ Mathijssen, JJ Swen… - The Lancet …, 2018 - thelancet.com
Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …